Barclays Starts Moderna, Inc. (MRNA) Neutral as Biotech Outlook Improves

We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy.

On January 28, Barclays assumed coverage of Moderna, Inc. (NASDAQ:MRNA) with an Equal Weight rating and a $25 price target as part of a broader biotechnology coverage expansion. The firm expressed a constructive view on the sector heading into 2026, citing undervaluation, expected M&A activity, and improving industry fundamentals as supportive factors.

During Moderna’s third-quarter 2025 earnings call, the company reported revenue of approximately $1.0 billion, driven primarily by sales of its approved vaccines, including Spikevax, mNEXSPIKE, and mRESVIA. Moderna, Inc. (NASDAQ:MRNA) ended the quarter with $6.6 billion in cash and investments and guided to a year-end balance of $6.5 billion to $7.0 billion. The company emphasized disciplined capital management while continuing to fund pipeline development across multiple therapeutic areas.

Moderna, Inc. (NASDAQ:MRNA) was founded in September 2010 and is headquartered in Cambridge, Massachusetts. The company focuses on developing medicines using messenger RNA technology. Moderna is second on the list of 10 best long term healthcare stocks to buy.

While we acknowledge the potential of MRNA as a long term investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 8 Up and Coming Streaming Companies and Services and 9 High Growth Canadian Stocks to Buy

Disclosure: None.